The treatment landscape for joint diseases like osteoarthritis and rheumatoid arthritis is poised for a significant breakthrough, thanks to an innovative licensing deal between Enveric Biosciences and Restoration Biologics. The agreement allows Restoration Biologics to develop and commercialize Enveric’s cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications, potentially reshaping pain management and regenerative medicine.
